MedTrace Logo

Facilitated Immunoglobulin Administration Registry and Outcomes Study (FIGARO)

NCT03054181 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2023-09-14

No results posted yet for this study

Summary

Long-term observational study on the utilisation and outcomes of HyQvia (a product consisting of recombinant human hyaluronidase and a human normal immunoglobulin 10% solution) under everyday clinical practice conditions.

Conditions

  • Primary Immunodeficiency
  • Secondary Immune Deficiency

Interventions

BIOLOGICAL

HyQvia

Sponsors & Collaborators

  • GWT-TUD GmbH

    lead OTHER

Principal Investigators

  • Michael Borte, MD, PhD · Fachbereich Pädiatrische Rheumatologie, Immunologie und Infektiologie am Klinikum St. Georg Leipzig

  • David Pittrow, MD · GWT-TUD GmbH, Dresden, Germany

  • Isabelle Quinti, MD · Sapienza University Rome, Italy

  • Leif Hanitsch, MD · Charité Berlin, Germany

  • Nizar Mahlaoui, MD · University Hospital, Paris, France

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-22
Primary Completion
2021-11-30
Completion
2021-11-30

Countries

  • France
  • Germany
  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03054181 on ClinicalTrials.gov